X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7596) 7596
Publication (569) 569
Book / eBook (226) 226
Book Review (121) 121
Book Chapter (50) 50
Newsletter (25) 25
Magazine Article (15) 15
Conference Proceeding (13) 13
Newspaper Article (6) 6
Trade Publication Article (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6770) 6770
female (4174) 4174
index medicus (3874) 3874
male (3668) 3668
adult (3065) 3065
hematology (2922) 2922
middle aged (2869) 2869
oncology (2491) 2491
aged (2179) 2179
transplantation (1438) 1438
cancer (1415) 1415
treatment outcome (1384) 1384
adolescent (1349) 1349
animals (1195) 1195
hematologic neoplasms - therapy (1187) 1187
chemotherapy (1091) 1091
hematologic malignancies (1067) 1067
immunology (1047) 1047
leukemia (995) 995
hematologic neoplasms - drug therapy (925) 925
child (915) 915
retrospective studies (915) 915
care and treatment (877) 877
hematologic diseases - chemically induced (858) 858
risk factors (835) 835
bone-marrow-transplantation (785) 785
health aspects (770) 770
pharmacology & pharmacy (756) 756
hematologic neoplasms - complications (755) 755
stem cells (747) 747
hematopoietic stem cells (738) 738
therapy (736) 736
antineoplastic agents - therapeutic use (713) 713
young adult (699) 699
antineoplastic combined chemotherapy protocols - therapeutic use (666) 666
hematopoietic stem cell transplantation (663) 663
research (641) 641
analysis (639) 639
pregnancy (609) 609
transplantation, homologous (609) 609
child, preschool (601) 601
aged, 80 and over (589) 589
antineoplastic agents - adverse effects (588) 588
medicine & public health (586) 586
acute myeloid-leukemia (582) 582
hematology, oncology and palliative medicine (555) 555
stem-cell transplantation (534) 534
blood (527) 527
versus-host-disease (522) 522
medicine (498) 498
mortality (495) 495
dose-response relationship, drug (490) 490
antineoplastic combined chemotherapy protocols - adverse effects (479) 479
prospective studies (468) 468
drug administration schedule (467) 467
antineoplastic agents - administration & dosage (460) 460
hematopoietic stem cell transplantation - adverse effects (442) 442
infectious diseases (442) 442
bone marrow (435) 435
hematologic tests (434) 434
survival analysis (433) 433
infant (432) 432
drug therapy (431) 431
diagnosis (425) 425
time factors (400) 400
disease-free survival (395) 395
follow-up studies (385) 385
prognosis (385) 385
patients (384) 384
transplantation conditioning - methods (384) 384
mice (381) 381
graft vs host disease - prevention & control (379) 379
hematopoietic stem cell transplantation - methods (375) 375
research article (374) 374
survival rate (373) 373
toxicity (371) 371
children (369) 369
hematologic neoplasms - mortality (368) 368
lymphoma (362) 362
pediatrics (359) 359
dosage and administration (357) 357
diseases (348) 348
hematologic diseases (347) 347
article (346) 346
pharmacokinetics (346) 346
neutropenia (338) 338
lymphomas (337) 337
medical research (335) 335
neoplasms - drug therapy (331) 331
antifungal agents - therapeutic use (330) 330
survival (325) 325
acute lymphoblastic-leukemia (317) 317
clinical trials as topic (316) 316
drug therapy, combination (312) 312
stem cell transplantation (310) 310
science (305) 305
hematologic neoplasms - pathology (304) 304
incidence (304) 304
multidisciplinary sciences (303) 303
hematologic diseases - therapy (302) 302
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (195) 195
Collection Dvlpm't (Acquisitions) - Closed Orders (11) 11
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Online Resources - Online (4) 4
Toronto East General Hospital - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7650) 7650
Japanese (113) 113
French (50) 50
Russian (34) 34
German (33) 33
Spanish (32) 32
Chinese (16) 16
Polish (12) 12
Italian (9) 9
Hungarian (6) 6
Czech (3) 3
Hebrew (2) 2
Norwegian (2) 2
Serbian (2) 2
Arabic (1) 1
Croatian (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 1, pp. 117 - 122
Abstract Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by... 
Hematology, Oncology and Palliative Medicine | Haploidentical transplantations | Acute leukemia | HLA | Posttransplantation cyclophosphamide | Allogeneic stem cell transplant | MORTALITY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | TRANSPLANTATION | REDUCED-INTENSITY | ACUTE-LEUKEMIA | HIGH-RISK | HAPLOTYPE | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | BLOOD | Hematologic Neoplasms - therapy | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Follow-Up Studies | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Transplantation, Homologous | Graft vs Host Disease - mortality | Antineoplastic Agents - adverse effects | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Acute Disease | Busulfan - adverse effects | Vidarabine - adverse effects | Survival Rate | Vidarabine - analogs & derivatives | Disease-Free Survival | Adolescent | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | Aged | Vidarabine - administration & dosage | Transplantation Conditioning | Chronic Disease | Thiotepa - adverse effects | Antimitotic agents | Pneumonia | Cyclophosphamide | Bacterial pneumonia | Mortality | Bone marrow | Transplantation | Antineoplastic agents | Cancer
Journal Article
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 9, pp. 2413 - 2419
To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated... 
CRITERIA | DEXAMETHASONE | AGENTS | HEMATOLOGY | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Prospective Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Feasibility Studies | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Hematopoietic Stem Cell Mobilization | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Multiple Myeloma - surgery | Immunosuppressive Agents - administration & dosage | Thalidomide - adverse effects | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Acute Disease | Immunologic Factors - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Remission Induction | Cyclosporine - therapeutic use | Disease-Free Survival | Melphalan - administration & dosage | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Cyclosporine - administration & dosage | Lymphocyte Count | Aged | Immunologic Factors - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
Blood, ISSN 0006-4971, 03/2014, Volume 123, Issue 12, pp. 1818 - 1825
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 641 - 650
Abstract We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Cyclophosphamide | Histocompatibility antigens | Conditioning regimens | Lymphoma | Leukemia | TOTAL-BODY IRRADIATION | leukemia | IMMUNE RECONSTITUTION | lymphoma | UNRELATED DONORS | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | bone marrow transplantation | TRANSPLANTATION | histocompatibility antigens | CORD BLOOD TRANSPLANTATION | DRUG-INDUCED TOLERANCE | IDENTICAL SIBLINGS | cyclophosphamide | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MYCOPHENOLATE-MOFETIL | conditioning regimens | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Recombinant Proteins | Bone Marrow Transplantation - methods | Cyclophosphamide - therapeutic use | Filgrastim | Transplantation, Homologous | Bone Marrow Transplantation - immunology | Adult | Female | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Drug Administration Schedule | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Postoperative Care - methods | Blood Component Transfusion | Hematologic Neoplasms - surgery | Disease-Free Survival | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Hemoglobinuria, Paroxysmal - surgery | Cyclophosphamide - pharmacology | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Histocompatibility | Antimitotic agents | Evaluation | Mortality | Bone marrow | Dosage and administration | Transplantation | Antineoplastic agents | T cells | Cancer | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 08/2013, Volume 27, Issue 8, pp. 1628 - 1636
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 13, pp. 2578 - 2585
Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in... 
RHEUMATOID-ARTHRITIS | BCR | B-CELL LYMPHOMA | RESPONSE CRITERIA | R-CHOP | THERAPEUTIC TARGET | PHASE-III | TYROSINE KINASE INHIBITOR | FOLLICULAR LYMPHOMA | HEMATOLOGY | EXPRESSION | Humans | Middle Aged | Neoplasm Proteins - physiology | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - enzymology | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Protein-Tyrosine Kinases - physiology | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Oxazines - administration & dosage | Syk Kinase | Lymphoma, Non-Hodgkin - drug therapy | Oxazines - pharmacology | Pyridines - therapeutic use | Hematologic Diseases - chemically induced | Pyridines - administration & dosage | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Treatment Outcome | Oxazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Oxazines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Intracellular Signaling Peptides and Proteins - physiology | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Journal Article
Regional Anesthesia and Pain Medicine, ISSN 1098-7339, 01/2010, Volume 35, Issue 1, pp. 64 - 101
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2011, Volume 56, Issue 1, pp. 78 - 84
Journal Article